Treatment of early uterine sarcomas: disentangling adjuvant modalities

Table 1 Summary of studies on adjuvant chemotherapy in early-stage uterine sarcomas.

Study	No of patients	Radiation	Regimens	Recurrence (%) at 5 years	5-year survival (%)
Buchsbaum et al, 1979 [94]	8	NR	VAC	37	63
Omura et al, 1985 [100]	64	No	DOX	39	53
van Nagel et al, 1986 [95]	7	No	VAC	29	86
Berchuck et al, 1988 [6]	12 LMS	Yes	Various	83	42
Piver et al, 1988 [105]	11	No	CyVADIC	18	89
Hempling et al, 1995 [96]	20	No	CyVADIC	35	68
Resnik et al, 1995 [101]	23 CS	No	Etoposide + cisplatin + DOX	22	92 (at 2 years)
Gadducci et al, 1996 [43]	11 LMS	2 patients	Various	39	NR
Sartori et al, 1997 [106]	5 CS	No	NR	40	NR
Chauveinc et al, 1999 [21]	24	Yes	Various	NR	NR
Kushner et al, 2000 [98]	10	No	IFO	50	67 (at 3 years)
Manolitsas et al, 2001 [102]	21 CS	Yes	various	9.5	95
Giuntoli et al, 2003 [44]	34 LMS	2 patients	Various	NR	NR
Pautier et al, 2004 [99]	16	Yes	API	28	100
Odunsi et al, 2004 [97]	24	No	CyVADIC	33	75
Sutton et al, 2005 [35]	65 CS	No	IFO + Cisplatin	35	62
Ti et al, 2006 [104]	51	Yes	various	59	67
Papadimitriou et al, 2007 [4]	31	12 patients	Anthracycline-based	39	54
Wolfson et al, 2007 [33]	101 CS	No	CIM	52	46

ISSN: 1477-7819